1217169-93-1
1217169-93-1
Chemical Structure
Amiloride-15N3
Synonym(s): MK-870-15N3
- CAS 番号: 1217169-93-1
- Formula:C6H8ClN415N3O
- Molecular Weight:232.61
InChIKey: XSDQTOBWRPYKKA-MKZAMGNXSA-N
SMILES: [15NH]=C([15NH2])[15NH]C(C1=NC(Cl)=C(N)N=C1N)=O
Biological Activity: Amiloride-15N3 (MK-870-15N3) is 15N labeled Amiloride. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]). Amiloride is a blocker of polycystin-2 (PC2; TRPP2[3]) channel.
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amiloride-15N3 | Amiloride-15N3 (MK-870-15N3) is 15N labeled Amiloride. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride is a blocker of polycystin-2 (PC2; TRPP2) channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amiloride (Standard) | 99.82% | Amiloride (Standard) is the analytical standard of Amiloride. This product is intended for research and analytical applications. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride is a blocker of polycystin-2 (PC2; TRPP2) channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amiloride | 99.96% | Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride is a blocker of polycystin-2 (PC2; TRPP2) channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Ji, H.L., et al. delta ENaC: a novel divergent amiloride-inhibitable sodium channel. Am J Physiol Lung Cell Mol Physiol, 2012. 303(12): p. L1013-26. [Content Brief]
- [3]. Teiwes J, et al. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007 Jan;20(1):109-17. [Content Brief]
